A Phase 1 Study of H3B-6545 in Japanese Women With Estrogen Receptor-positive, HER2 Negative Breast Cancer
Latest Information Update: 28 Sep 2023
At a glance
- Drugs H3B-6545 (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Adverse reactions
- Sponsors Eisai Co Ltd
- 25 Sep 2023 Planned End Date changed from 30 Nov 2023 to 31 Aug 2024.
- 25 Sep 2023 Planned primary completion date changed from 30 Nov 2023 to 31 Aug 2024.
- 19 Dec 2022 Planned End Date changed from 28 Feb 2023 to 30 Nov 2023.